SynthesisBMC cancer2023

Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials.

Zhiwen Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.